Close Menu

More articles about Reproductive Health

The company ran 668,600 tests during the year, a 30 percent increase from its 2017 testing volume.

Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."

The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.

Last week, Invitae launched its Non-Invasive Prenatal Screening test while Myriad expanded its Prequel Prenatal Screen to cover all aneuploidies.

The new channel, to be launched in the second quarter, is part of the company's plan to make genetic testing affordable and accessible to everyone.

Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.

The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.

Based on gene expression, researchers identified cell clusters in testes samples from two adult men and two infants, providing clues that may eventually aid fertility treatments.

Two new studies found that prenatal whole-exome sequencing could uncover clinically significant variants in an additional 8 to 12 percent of fetuses with structural anomalies.

The firm plans to use the funding to drive sales of its preimplantation genetic screening tests and to invest in data science.

Illumina continues to forge partnerships with diagnostic developers overseas as it eyes approximately 50 population sequencing projects around the world.

The firm also continues to use its methylation-specific PCR technology to develop assays for partners in the oncology space.

The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.

The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.

Researchers tested the combined PGS and PGD assay in a pilot study and now aim to validate it on larger numbers of disorders and compare it to conventional testing.

A GWAS meta-analysis involving 10,074 PCOS cases revealed three new and 11 known risk loci, along with a relatively consistent genetic architecture among cases.

The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.

The researchers suggested that the regions they found should be included in diagnostic assays for unexplained cases of disorders of sex development.

The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.

The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.